Abacavir/3TC co-formulation available in expanded access
2 May 2004. Related: Antiretrovirals.
2004
Eating grapefruit triggers statin-related rhabdomyolysis
2 May 2004. Related: PK and drug interactions, Side effects.
FDA panel recommends approval of New-fill
2 May 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Lipodystrophy regresses in three patients switched to atazanavir
2 May 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Post partum complications in HIV-positive women
2 May 2004. Related: Pregnancy.
Children’s HIV National Network (CHINN) Review
2 May 2004. Related: Paediatric care.
FDA approves new paediatric dose of nelfinavir
2 May 2004. Related: Paediatric care.
Surgery and HAART are an effective combination for treating HPV-associated lesions
2 May 2004. Related: Cancer and HIV.
Postexposure prophylaxis does not lead to an increase in high-risk behaviour
2 May 2004. Related: Other news.
Law would permit HIV-positive organ donation
2 May 2004. Related: Other news.
A guide to applying to the Global Fund is released
2 May 2004. Related: Other news.
Conference reports
2 May 2004. Related: On the web.
Online medical training
2 May 2004. Related: On the web.
Newletters and journals
2 May 2004. Related: On the web.
Volume 5 Number 4 May 2004 PDF
1 May 2004. Related: PDFs.
Treatment with generics: tolerability, safety and resistance
5 April 2004. Related: Antiretrovirals, Treatment access.
Volume 5 number 3 April 2004
3 April 2004. Related: Editorial.
Risk factors for severe, life-threatening and fatal hepatotoxicity with nevirapine
3 April 2004. Related: Treatment alerts.
11th Conference on Retroviruses and Opportunistic Infections (CROI)
3 April 2004. Related: Conference reports.
Drug levels can persist for more than two weeks after stopping efavirenz
3 April 2004. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Race affects absorption and clearance of efavirenz
3 April 2004. Related: Conference reports, PK and drug interactions, Side effects.
Triple PI interactions: atazanavir increases saquinavir levels in ritonavir-boosted once-daily combination
3 April 2004. Related: Conference reports, PK and drug interactions.
Triple PI interactions: fosamprenavir and Kaletra interaction is difficult to overcome
3 April 2004. Related: Conference reports, PK and drug interactions.
Ribavirin (RBV) does not alter intracellular levels of AZT, 3TC or d4T
3 April 2004. Related: Conference reports, PK and drug interactions, Hepatitis coinfection.
COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation
3 April 2004. Related: Conference reports, Antiretrovirals.
Studies of new pipeline drugs
3 April 2004. Related: Conference reports, Antiretrovirals.
Little benefit seen for treatment during acute infection
3 April 2004. Related: Conference reports, Antiretrovirals, Basic science and immunology.
Summary of resistance studies at Retrovirus
3 April 2004. Related: Conference reports, Drug resistance.
Update on peripheral neuropathy in HIV-infection
3 April 2004. Related: Conference reports, Side effects.
Smoking marijuana provides analgesic effect on HIV neuropathy
3 April 2004. Related: Conference reports, Side effects.
Two D:A:D updates: cardiovascular risk from HAART, and predictors of hypertension and changes in blood pressure
3 April 2004. Related: Conference reports, Side effects.
Low-dose rHGH maintains reductions in abdominal fat for 60 weeks
3 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Rosiglitazone shows no benefit for lipoatrophy
2 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Hypertension related to HAART in HIV-positive women
2 April 2004. Related: Conference reports, Women's health.
Testosterone therapy for women with low androgen levels or body weight
2 April 2004. Related: Conference reports, Women's health.
Nevirapine, pregnancy and adverse events
2 April 2004. Related: Conference reports, Pregnancy.
Prior nevirapine exposure for pregnant women can contribute to treatment failure
2 April 2004. Related: Conference reports.
Conflicting findings with HAART use in pregnancy and prematurity
2 April 2004. Related: Conference reports, Pregnancy.
Antiretrovirals, mode of delivery and transmission risk
2 April 2004. Related: Conference reports, Pregnancy.
Tenofovir studies in children
2 April 2004. Related: Conference reports, Paediatric care.
Increase of non-AIDS defining cancers in HOPS cohort
2 April 2004. Related: Conference reports, Cancer and HIV.
HIV/HCV coinfection: superiority of pegylated interferon plus ribavirin, but lower response rate compared to mono-infected patients, especially for genotype-1
2 April 2004. Related: Conference reports, Hepatitis coinfection.
Epoetin-alfa improves interferon/ribavirin-associated anaemia
2 April 2004. Related: Conference reports, Hepatitis coinfection.
Gilead discontinues DAPD development
2 April 2004. Related: Antiretrovirals.
International community meeting on drug pricing
2 April 2004. Related: Treatment access.
Global Fund halts $92 million grant for Ukraine after problems
2 April 2004. Related: Treatment access.
Global Fund says it needs $5 billion during 2004-2005
2 April 2004. Related: Treatment access.
South African minister of health in line to chair Global Fund
2 April 2004. Related: Treatment access.
Thai ddI patent case serves as example to other developing countries, Lancet viewpoint piece says
2 April 2004. Related: Treatment access.
UK gives £3 million to WHO’s ‘3 by 5’ treatment goal
2 April 2004. Related: Treatment access.
International panel issues new guidelines for the care of HIV-HCV coinfected patients
2 April 2004. Related: Hepatitis coinfection.
NICE approves pegylated interferon plus ribavirin in UK
2 April 2004. Related: Hepatitis coinfection.
New HIV cases in England and Wales increase by 20% in past year
2 April 2004. Related: Other news.
Micronutrient supplements may enhance survival; research has implications for poor countries
2 April 2004. Related: Other news.
Durex withdraws N-9 condoms
2 April 2004. Related: Other news.
Medical resources
2 April 2004. Related: On the web.
Volume 5 Number 3 April 2004 PDF
1 April 2004. Related: PDFs.
Volume 5 Number 1/2 February/March 2004
3 February 2004. Related: Editorial.
Abbott raises price of ritonavir in the US by over 400%
3 February 2004. Related: Antiretrovirals.
Development of T-1249 put on hold
3 February 2004. Related: Antiretrovirals.
Tenofovir/abacavir/3TC triple-nuke fails as maintenance regimen
3 February 2004. Related: Antiretrovirals.
New data on viral load ‘blips’ and the link to replication
3 February 2004. Related: Antiretrovirals.
Invirase and Fortovase: new dosing regimens approved by FDA
3 February 2004. Related: Antiretrovirals.
UK named-patient access to tipranavir
3 February 2004. Related: Antiretrovirals.
FDA labelling changes for indinavir (Crixivan)
3 February 2004. Related: Antiretrovirals.